CERo Therapeutics Holdings Management
Management criteria checks 0/4
CERo Therapeutics Holdings' CEO is Chris Ehrlich, appointed in Sep 2024, has a tenure of 1.17 years. total yearly compensation is $1.99M, comprised of 4.5% salary and 95.5% bonuses, including company stock and options. directly owns 0.16% of the company’s shares, worth $204.44. The average tenure of the management team and the board of directors is 1.1 years and 1.8 years respectively.
Key information
Chris Ehrlich
Chief executive officer
US$2.0m
Total compensation
| CEO salary percentage | 4.53% |
| CEO tenure | 1.2yrs |
| CEO ownership | 0.2% |
| Management average tenure | 1.1yrs |
| Board average tenure | 1.8yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2025 | n/a | n/a | -US$42m |
| Mar 31 2025 | n/a | n/a | -US$14m |
| Dec 31 2024 | US$2m | US$90k | -US$11m |
Compensation vs Market: Chris's total compensation ($USD1.99M) is above average for companies of similar size in the US market ($USD600.00K).
Compensation vs Earnings: Insufficient data to compare Chris's compensation with company performance.
CEO
Chris Ehrlich (55 yo)
Mr. Christopher B. Ehrlich, M.B.A. also known as Chris, serves as Chief Executive Officer & Chair of CERo Therapeutics, Inc. Mr. Ehrlich was Director at ProLynx Inc since September 2022 until 2023. He serv...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chair | 1.2yrs | US$1.99m | 0.16% $ 204.4 | |
| Chief Financial Officer | 1.1yrs | US$291.41k | 0% $ 0 | |
| Chief Development Officer | 1.1yrs | US$389.78k | 0% $ 0 | |
| Co-founder & Head of Scientific Advisory Board | no data | no data | 0% $ 0 |
Experienced Management: CERO's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chair | 1.8yrs | US$1.99m | 0.16% $ 204.4 | |
| Co-founder & Head of Scientific Advisory Board | no data | no data | 0% $ 0 | |
| Director | 1.8yrs | US$1.94m | 1.32% $ 1.7k | |
| Independent Director | 1.8yrs | US$26.25k | 0.026% $ 34.3 | |
| Independent Director | 1.1yrs | US$112.50k | 0% $ 0 | |
| Scientific Advisor | no data | no data | no data | |
| Scientific Advisor | no data | no data | no data | |
| Scientific Advisor | no data | no data | no data | |
| Independent Director | 1.8yrs | US$26.25k | 0% $ 0 | |
| Independent Director | 1.8yrs | US$26.25k | 0% $ 0 |
Experienced Board: CERO's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/03 19:59 |
| End of Day Share Price | 2025/11/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
CERo Therapeutics Holdings, Inc. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Kolbert | D. Boral Capital LLC. |
| Jason McCarthy | Maxim Group |